Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective (vol 43, pg S1, 2021)

被引：0

作者：

Salvino, M. A. ^{[1
,2
]}

Bonfim, C. ^{[3
]}

Calado, R. T. ^{[4
]}

Kim, H. ^{[5
]}

Bertinato, J. F. ^{[5
]}

Scheinberg, P. ^{[6
]}

机构：

[1] Univ Fed Bahia UFBA, HUPES, Salvador, BA, Brazil

[2] Hosp Sao Rafael, Inst DOr Ensino & Pesquisa IDOR, Salvador, BA, Brazil

[3] Univ Fed Parana UFPR, Dept Hematol, Blood & Marrow Transplantat Unit, Hosp Clin, Curitiba, PR, Brazil

[4] Univ Sao Paulo, FMRP, Dept Med Imaging Haematol & Clin Oncol, Curitiba, PR, Brazil

[5] Novartis Biociencias SA, Sao Paulo, SP, Brazil

[6] Beneficencia Portuguesa Sao Paulo BP, Div Hematol, Sao Paulo, SP, Brazil

来源：

HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2022年 / 44卷 / 02期

关键词：

D O I：

10.1016/j.htct.2022.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 1

页数：1

共 35 条

[1] COST-EFFECTIVENESS OF NIVOLUMAB VERSUS DACARBAZINE IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FROM BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Casagrande Oliveira, A. P.
Hamza, S.
Koloszuk, A.
Marinheiro, P.
Bernardino, G.
[J]. VALUE IN HEALTH, 2020, 23 : S41 - S41
[2] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Holanda, P.
Salgado De Santana, C.
Senna, T.
Carmo, L.
Alexandre, R. F.
[J]. VALUE IN HEALTH, 2021, 24 : S96 - S96
[3] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Ferreira, P.
Senna, T.
Sebastiao, M.
Alexandre, R. F.
Almeida, P.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S68 - S69
[4] COST-EFFECTIVENESS ANALYSIS OF TRANSTHYRETIN-ASSOCIATED AMYLOID CARDIOMYOPATHY FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Sebastiao, M.
Ferreira, P.
Senna, T.
Alexandre, R. F.
Almeida, P.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S156 - S156
[5] Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis
Tremblay, Gabriel
Said, Qayyim
Cai, Beilei
Garib, Shan Ashton
Tomaras, Dimitrios
Forsythe, Anna
Roy, Anuja
[J]. BLOOD, 2018, 132
[6] AMINO ACID FORMULA AS A FIRST-LINE DIAGNOSIS TOOL IN INFANTS WITH COW'S MILK ALLERGY (CMA): A COST-EFFECTIVENESS ANALYSIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Castro, A. P. B. M.
Morais, M. B. D.
Cardoso, A. L.
Vieira, M. C.
Spolidoro, J. V. N.
Nishikawa, A. M.
Clark, O. A. C.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A176 - A176
[7] Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for BRAF mutant patients from a Brazilian private payer perspective.
Lima, Joao Psdn
Matteucci, Christina
Bernardino, Graziela
Oliveira, Ana Paula
Maia, Daniela Galdeano
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain (vol 13, pg 263, 2021)
Mareque, M.
Montesinos, P.
Font, P.
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 645 - 645
[9] FIRST-LINE PEMBROLIZUMAB IN PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS FROM A UK HEALTHCARE PERSPECTIVE
Hu, X.
Goldman, D. P.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A399 - A399
[10] Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.
Matteucci, Christina
Lima, Joao P. S. D. N.
Bernardino, Graziela
Oliveira, Ana Paula
Maia, Daniela Galdeano
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 →